Stifel Financial Corp Purchases 58,657 Shares of Precigen, Inc. (NASDAQ:PGEN)

Stifel Financial Corp lifted its position in Precigen, Inc. (NASDAQ:PGEN) by 182.2% during the 4th quarter, Holdings Channel reports. The firm owned 90,857 shares of the biotechnology company’s stock after acquiring an additional 58,657 shares during the period. Stifel Financial Corp’s holdings in Precigen were worth $102,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. lifted its position in Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 5,915 shares during the period. RPO LLC bought a new position in Precigen in the 4th quarter worth about $47,000. Invesco Ltd. boosted its stake in Precigen by 14.6% in the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 6,040 shares in the last quarter. SG Americas Securities LLC boosted its stake in Precigen by 27.9% in the 4th quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,578 shares in the last quarter. Finally, Stoneridge Investment Partners LLC raised its position in Precigen by 21.3% in the 4th quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after buying an additional 12,063 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Analysts Set New Price Targets

PGEN has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Precigen in a research report on Thursday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Precigen in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Precigen Price Performance

NASDAQ:PGEN opened at $1.31 on Friday. The firm has a market cap of $386.67 million, a price-to-earnings ratio of -2.38 and a beta of 1.82. The company has a 50 day moving average price of $1.50 and a 200-day moving average price of $1.29. Precigen, Inc. has a 1-year low of $0.65 and a 1-year high of $2.17.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $0.50 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. On average, sell-side analysts anticipate that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.